RT Journal Article
SR Electronic
T1 Cause-Specific Excess Mortality in the US During the COVID-19 Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.05.24303783
DO 10.1101/2024.03.05.24303783
A1 Degtiareva, Ekaterina
A1 Tilstra, Andrea M.
A1 Schöley, Jonas
A1 Kashyap, Ridhi
A1 Dowd, Jennifer B.
YR 2024
UL http://medrxiv.org/content/early/2024/03/07/2024.03.05.24303783.abstract
AB The COVID-19 pandemic was a significant shock to United States mortality, and it is important to understand how the pandemic impacted other causes of death. We estimated monthly excess mortality in the US by cause of death, age, and sex, for official deaths at ages 15 and older. Data come from the CDC Wonder Multiple Cause of Death database. We used a compositionally robust Generalized Additive Model (GAM) to estimate expected mortality counts in March 2020-December 2022 for eight causes of death: accidents, cardiovascular diseases, cancer, diabetes, influenza and pneumonia, substance-related (drugs and alcohol), suicide, and residual (including COVID-19 related deaths). Analyses were stratified by sex and 15-year age groups from 15-29 to 75+. Excess mortality was calculated as observed deaths minus expected deaths. From March 2020 to December 2022, we estimated 1 298 763 total excess deaths (95% CI: 1 226 542 to 1 370 804). While there were fewer deaths than expected due to some causes like flu/pneumonia and suicide, the largest number of excess deaths, excluding COVID-19, were attributed to cardiovascular diseases (115 765 deaths, 95% CI: 98 697 to 133 783) and substance use (86 637 deaths, 95% CI: 79 273 to 93 690). Percent excess substance-related mortality was high across all ages, while percent excess from cardiovascular diseases was highest at midlife ages. Some of these excess cardiovascular deaths were likely due to undercounted COVID-19 deaths, but others may reflect indirect impacts of the pandemic on healthcare utilization or longer-term effects of COVID-19 infections.SIGNIFICANCE STATEMENT The COVID-19 pandemic increased mortality directly due to COVID-19 deaths, but also changed the pattern of deaths due to other causes in the United States. We estimated excess cause-specific mortality in the US and present several findings. We estimated nearly 1.3 million total excess deaths in the US from March 2020 to December 2022. Deaths from suicide and influenza and pneumonia were lower than expected based on previous trends, but deaths due to cardiovascular diseases, diabetes, accidents, and substance-related causes (drug and alcohol) were higher. Cancer deaths were generally unchanged. By quantifying both the direct and indirect effects of the COVID-19 pandemic on US mortality, we highlight areas of on-going vulnerability in the US.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the Leverhulme Trust (Grant RC-2018-003) for the Leverhulme Centre for Demographic Science (ED, AMT, JD), the European Research Council grant ERC-2021-CoG-101002587 (ED, AMT, JD), the UK Research and Innovation (UKRI) under the UK government Horizon Europe funding guarantee EP-X027678-1 (AMT). Previous versions of this manuscript benefited from feedback provided by the Leverhulme Centre for Demographic Science Health Inequality Working Group. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the ERC, the UKRI, or the Leverhulme Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMaterials for reproduction, including metadata and scripts, will be available at peer review and upon publication.